Roche Signs $2.5B Deal for Hanmi’s Clinical-Stage Obesity Drug

By Dr. Zubair Khalid, DVM, MS, PhD ·

Roche Signs $2.5B Deal for Hanmi’s Clinical-Stage Obesity Drug

Key Takeaways

  • Roche has acquired rights to a clinical-stage obesity drug from Hanmi Pharm, involving an upfront payment of $190 million and potential milestone payments totaling up to $2.5 billion.
  • The drug is a urocortin-2 analog, targeting a biological mechanism distinct from the prevalent GLP-1 receptor agonists and related incretin pathways currently dominating the obesity treatment landscape.
  • Urocortin-2 is a peptide involved in stress response and energy regulation, with its specific role in promoting weight loss being investigated in ongoing clinical trials.
  • This strategic move by Roche aims to diversify therapeutic options for obesity, a global health challenge affecting hundreds of millions, by exploring novel biological pathways.
  • The development of drugs targeting alternative mechanisms like urocortin-2 may offer solutions for patient populations who exhibit suboptimal responses to existing incretin-based therapies.

Roche has entered into a licensing agreement with South Korea’s Hanmi Pharm for a clinical-stage obesity drug that targets a less-explored mechanism. The deal includes a $190 million upfront payment and could reach up to $2.5 billion in total milestone payments.

The drug is a urocortin-2 analog, a type of compound that acts on a different biological pathway than most current obesity treatments. Urocortin-2 is a peptide related to stress response and energy regulation, though its role in weight loss is not yet fully established in large-scale clinical trials.

Why it matters: Most approved obesity drugs target GLP-1 or related incretin pathways. By pursuing a urocortin-2 mechanism, Roche is exploring a distinct biological approach to weight management. If successful, this could expand the range of treatment options for obesity, a condition affecting hundreds of millions of people worldwide. Diversifying the mechanisms used in obesity therapy may also help address patient populations who do not respond well to existing drugs.

Source: original report